Professor of Medical Biochemistry Klaus Elenius from the University of Turku has been selected for the position of the Scientific Director of BioCity Turku.
The vacancy lasts five years and started on 1 January 2022.
A key position
BioCity Turku is a joint organization of the University of Turku and Åbo Akademi University, supporting and coordinating bioscience research in the Turku region. The key responsibilities of the Scientific Director are developing and coordinating research as well as postgraduate and continuing education, developing the research environment and infrastructure; and promoting collaboration between researchers in bioscience and medical research. The international BioCity Turku research community currently comprises more than 140 research groups.
“BioCity Turku has a key position in representing and coordinating research in bioscience both on a national and regional level. In the Turku region, BioCity Turku has a unique opportunity to support the researchers’ networking between two different universities, the University Hospital, and an exceptionally active business field,” says Elenius.
The Scientific Director of BioCity Turku also acts as the chairperson of the common Executive Board of BioCity Turku and the Turku Bioscience Centre. Moreover, the Scientific Director contributes to the development of Biocenter Finland and participates in its decision-making processes.
Klaus Elenius has had a remarkable career in e.g. the research of cancers and heart diseases. Since 1998, Elenius has led his own research group at the Institute of Biomedicine of the University of Turku, in the MediCity research laboratory, where he has been the Vice Director since 2000. Elenius has been a Professor of Medical Biochemistry since 2010.
As a recognition of his merits in his academic career, Professor Elenius was invited as a member of the Finnish Academy of Science and Letters in 2020, and he is an active member in several Finnish and international organisations. In June 2021, Elenius was appointed as a member of the Board of the Academy of Finland for the term 2022–2024.
Professor Klaus Elenius also has broad collaboration networks in the fields of biomedicine and cancer research both in Finland and internationally. Elenius has participated in establishing a company called Abonomics Ltd, and he has had research contracts with several companies in the medical field.
“Modern research cannot be conducted on a high level without coordination and networking between experts in different fields. In this collaboration, research funders, universities and hospitals where the research is conducted, and the corporate world which further develops the findings each have their own, necessary role,” says Elenius.
Photo of Klaus Elenius: Suvi Harvisalo